ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

Oncolytics Biotech received FDA alignment on a registrational pathway for pelareorep in metastatic colorectal cancer, enabling a potential pivotal trial expansion with accelerated and full approval strategies. The FDA also granted Fast Track designation for pelareorep in advanced anal cancer, expediting development and review.

This Wire brief sits within Fusion42's coverage of Biotech.